May 26, 2005
Note: One or more of the following articles may require a subscription to view the entire article. We cannot post articles that require a subscription. We are sorry for the inconvenience.
Bipolar disorder harder on kids
for Bipolar Depression Treatment
children for bipolar disorder
Investigational Data Using Intramuscular Administration of ...
Writer wants editors' mental health records
Mental health center has new director
Council will lead mental health probe
Electric shock reduces heart disease in depression
MORE COVERAGE FOR MENTAL HEALTH CARE NEEDED
The Post-Standard (Syracuse, NY); 5/23/2005
To the Editor:
As founder of the CNY Depression Support Group and president of the board of directors of the Mental Health Association of Onondaga County, I have a few comments concerning your lack of coverage of an extremely important health issue.
I was very disappointed that 50 press releases about a guest speaker on depressive disorders were sent to the news media and evidently The Post-Standard did not think it newsworthy enough to print.
I felt it both a privilege and an honor to have Dr. Anil Verma, a noted psychiatrist, speak to our group, the CNY Depression and Bipolar Support Group, on May 17 to answer questions concerning depressive disorders. There was minimal mention of it at all in the news media. I have made several attempts to appear on local radio talk shows and I regret to say, I have not had any success in informing the public as to what is available in their very own community.
People afflicted with this widespread and pervasive illness need to know they have a support system right here in Syracuse. They must not suffer alone in their deep despair. The purpose of our group is to educate, to let these people who suffer in silence know we care, we understand and we are there for them.
Our group meets every first and third Tuesday of each month at Transitional Living Services.
Gregg Phillips, president,
board of directors,
Mental Health Association of
COPYRIGHT 2005 All rights reserved. Reproduced with the permission of The Herald Co. by the Gale Group, Inc.
Award-Winning Documentary on Schizophrenia to Be Screened at 2005 American Psychiatric Association Meeting.
PR Newswire; 5/23/2005
'Out of the Shadow' Filmmaker to Discuss Her Mother's Illness and Barriers to Care
ATLANTA, May 23 /PRNewswire/ -- The award-winning documentary, Out of the Shadow, which illuminates the national plight of schizophrenia through one family's struggle, will be shown at a screening for 1000 mental health professionals at the annual meeting of the American Psychiatric Association in Atlanta, Georgia. The event will take place on Monday, May 23, at 6:30 pm at the Hyatt Regency Atlanta, Centennial Ballroom I/II.
The film will be introduced by Dr. Michael Hogan, Chair of the President's New Freedom Commission on Mental Health and Director of the Ohio Department of Mental Health. Following the film, acclaimed filmmaker Susan Smiley will participate in an 'up close and personal' question and answer session moderated by Dr. Ken Duckworth, Medical Director of the National Alliance for the Mentally Ill (NAMI) and Assistant Professor of Psychiatry at Harvard Medical School.
The making of Out of the Shadow was a personal journey for director/producer Susan Smiley, whose mother, Millie, lives with schizophrenia. The film, an official selection at the Vancouver Film Festival and SILVERDOCS: the AFI/Discovery Channel Film Festival, offers a frank look at this complex disease, dispels stigma and misconceptions surrounding schizophrenia, and presents the challenges Smiley's family has faced while navigating the public health system.
"Creating Out of the Shadow has allowed me to translate my personal challenges living with a loved one with schizophrenia into advocacy," said Smiley. "The film demonstrates that schizophrenia can be effectively managed when patients receive comprehensive psychosocial services, including safe and stable housing, family support and access to the latest medications," said Smiley.
Schizophrenia is a serious brain disorder that affects how a person thinks, feels and acts. More than 2 million people in the United States live with schizophrenia.
"Out of the Shadow offers an honest portrayal of schizophrenia and the profound challenges family caregivers face when navigating the public health system on behalf of loved ones with this serious brain disorder," said Ken Duckworth, MD. "The film underscores the importance of access to quality care and is a call to action for mental health professionals and policymakers alike," he added.
The post-film discussion with Smiley and Dr. Duckworth will tackle issues including:
* Access - Ensuring that all people living with schizophrenia
The film screening is supported by Janssen Pharmaceutica
Additional resources can be found at: http://www.outoftheshadow.com/
About Janssen - Based in Titusville, N.J., Janssen Pharmaceutica Products, L.P. currently markets prescription medications for the treatment of schizophrenia and bipolar disorder. For more information, visit http://www.janssen.com/.
CONTACT: Srikant Ramaswami Nicole Barsamian
CONTACT: Srikant Ramaswami, Janssen Pharmaceutica, +1-609-730-2612, +1-609-647-8195 (mobile); Nicole Barsamian, Barsamian Associates, +1-212-595-5749, +1-917-692-5037 (mobile), for Janssen Pharmaceutica Products
Web site: http://www.janssen.com/ http://www.outoftheshadow.com/ http://www.nami.org/ http://www.mentalwellness.com/
COPYRIGHT 2005 PR Newswire Association LLC
New Study Showed Efficacy was Most Important Factor in Decision to Stay on Antipsychotic Treatment for Schizophrenia.
PR Newswire; 5/23/2005
Findings also showed patients taking olanzapine stayed on treatment longer than other antipsychotics
ATLANTA, May 23 /PRNewswire-FirstCall/ -- People taking atypical antipsychotics for schizophrenia were most likely to discontinue therapy due to continued presence of psychiatric symptoms, according to data presented today at the 158th annual meeting of the American Psychiatric Association (APA). Findings also revealed that patients taking olanzapine were significantly more likely to remain on medication longer than patients taking other atypical and conventional antipsychotics.
"Schizophrenia is a chronic disease that requires lifelong therapy. Finding a medication to which patients will adhere is essential," said Michael Stevens, M.D., director of Psychopharmacology Research at Valley Mental Health in Salt Lake City, Utah. "These data demonstrated that patients with schizophrenia were more likely to stay on medication longer with olanzapine compared to other antipsychotics."
Almost 60 percent of people with schizophrenia do not take their medications as prescribed by their physicians.(1) According to the APA's guidelines for the treatment of schizophrenia, 60 to 70 percent of patients relapse within one year without maintenance treatment and almost 90 percent relapse within two years.(2)
In the study, "Differential Rates of Treatment Discontinuation in Clinical Trials as a Measure of Treatment Effectiveness of Atypical Antipsychotics," researchers reviewed treatment discontinuation rates and reasons for discontinuation from four 24 to 28 week randomized, double-blind clinical trials involving 1627 patients with schizophrenia taking widely prescribed atypical antipsychotics (olanzapine, risperidone, quetiapine and ziprasidone). The study compared discontinuation rates and the probability of staying on medication for patients taking olanzapine against patients taking the other atypicals. According to the study:
* Olanzapine-treated patients (n=822) were significantly more likely to stay on medication longer (19.1 vs. 16.1 weeks, p. <0.0001) and to complete the full duration of the trial (53.9 vs. 39.3 percent, p. <0.001) than patients treated with the other atypicals (n=805);
* Patients taking the other atypicals were significantly more likely to discontinue their medication due to poor response (lack of efficacy) or a worsening of psychiatric symptoms (such as hallucinations, delusions, depression and agitation) than patients taking olanzapine (other atypicals 24.6 percent vs. olanzapine 14.2 percent, p. <0.0001);
* Poor response and symptom worsening were the primary reasons for discontinuation (36 percent), regardless of medication, based on physician and patient perceptions; and
* There was no significant difference in the rate of discontinuation due to patients' inability to tolerate medication related to adverse events or side effects (olanzapine 5.6 percent vs. other atypicals 7.5 percent, p=0.13).
The data were collected in clinical, controlled settings and as a result might not reflect naturalistic treatment.
In a second, open-label, one-year trial, "Time to All-Cause Discontinuation Following Randomization to Open-label Olanzapine, Risperidone, or Conventional Antipsychotic Treatment for Schizophrenia," patients randomized to olanzapine (n=222), risperidone (n=217), or conventional antipsychotics (n=209) of low (n=14), medium (n=135; perphenazine n=49) or high potency (n=49) were compared on time to all-cause medication discontinuation. In the treatment of schizophrenia, time to all-cause medication discontinuation is a recognized index used to measure an interruption or cessation of antipsychotic treatment for any reason.
Survival rate analyses were used to compare the rates of patients remaining on the medication they were randomized to during the one-year study period. Mean number of days to all-cause discontinuation of the randomized medication were also calculated and compared between the treatment groups.
According to the study:
* Average time to all-cause discontinuation for olanzapine was significantly longer (274 days) than for risperidone (228 days, p<0.01), perphenazine (202 days, p<0.01) and other conventionals, regardless of potency levels (p<0.05);
* One-year survival rate was significantly higher for olanzapine (55 percent) than risperidone-treated patients (47 percent, p=0.006);
* Survival rate for olanzapine-treated patients was significantly higher (32 percent, p<0.001) than conventional antipsychotics of high, medium (including perphenazine) or low potency levels; and
* Survival rate for risperidone-treated patients was significantly higher (p<.01) than conventional antipsychotics of high or medium potency, but did not differ significantly (p<.05) from conventionals of low potency or perphenazine.
"An effective medication needs to be one that patients will feel motivated to continue," said Dr. Stevens. "These studies showed that patients taking olanzapine stayed on treatment longer than other antipsychotics, and shows that antipsychotics differ when comparing time to all-cause medication discontinuation."
Schizophrenia is a severe and debilitating psychiatric illness often characterized by acute psychotic episodes including delusions (false beliefs that cannot be corrected by reason), hallucinations (usually in the form of non-existent voices) and long-term impairments such as diminished emotion, lack of interest and depressive signs and symptoms. In addition to psychiatric symptoms, patients with schizophrenia are at greater risk for medical comorbidities than the general population.
Olanzapine (Eli Lilly and Company) is indicated for the treatment of schizophrenia, for acute bipolar mania, and for maintenance treatment in bipolar disorder.
Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.
The most common treatment-emergent adverse event associated with olanzapine in placebo-controlled, short-term schizophrenia and bipolar mania trials was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite, and tremor.
The most common treatment-emergent adverse event associated with olanzapine in combination with lithium or divalproex in 6-week combination bipolar mania trials was dry mouth. Other common events were weight gain, increased appetite, dizziness, back pain, constipation, speech disorder, increased salivation, amnesia, and paresthesia.
Hyperglycemia and diabetes mellitus -- Hyperglycemia, in some cases associated with ketoacidosis, coma, or death, has been reported in patients treated with atypical antipsychotics including olanzapine. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. All patients taking atypicals should be monitored for symptoms of hyperglycemia. Persons with diabetes who are started on atypicals should be monitored regularly for worsening of glucose control; those with risk factors for diabetes should undergo baseline and periodic fasting blood glucose testing. Patients who develop symptoms of hyperglycemia during treatment should undergo fasting blood glucose testing.
Safety experience in elderly patients with dementia-related psychosis -- In placebo-controlled clinical trials of elderly patients with dementia- related psychosis, the incidence of death in olanzapine-treated patients was significantly greater than placebo-treated patients (3.5% vs. 1.5%, respectively). Risk factors that may predispose this patient population to increased mortality when treated with olanzapine include age >80 years, sedation, concomitant use of benzodiazepines, or presence of pulmonary conditions (e.g., pneumonia, with or without .phpiration). Olanzapine is not approved for the treatment of patients with dementia-related psychosis.
Cerebrovascular adverse events (CVAE), including stroke, in elderly patients with dementia -- Cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, were reported in patients in trials of olanzapine in elderly patients with dementia-related psychosis. In placebo-controlled trials, there was a significantly higher incidence of CVAE in patients treated with olanzapine compared to patients treated with placebo. Olanzapine is not approved for the treatment of patients with dementia-related psychosis.
Prescribing should be consistent with the need to minimize the risk of neuroleptic malignant syndrome, tardive dyskinesia, seizures, and orthostatic hypotension.
For full prescribing information visit http://www.lilly.com/ .
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com/ .
LillyAnswers ensures that low-income Medicare enrollees with the greatest need have complete access to the Lilly products they require. The centerpiece of the patient assistance program, the LillyAnswers card, allows seniors and people with disabilities under Medicare to pay a flat $12 fee for a 30-day supply of certain retail distributed Lilly drugs, including olanzapine. Since Lilly implemented LillyAnswers in 2002, hundreds of thousands of people without prescription drug insurance have received more than a half million Lilly products. LillyAnswers enrollment applications are available by calling the toll-free number: 1-877-RX-LILLY (1-877-795-4559) or online at http://www.lillyanswers.com/ . P-LLY
This press release contains forward-looking statements about the potential of olanzapine for the treatment of schizophrenia and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
(1) Gilmer TP, Dolder CR, Lacro JP, Folsom DP, Lindamer L, et al. "Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia." Am J Psychiatry 2004 161: 692-699.
(2) Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004 Feb;161(2 Suppl):1-56.
CONTACT: Kerry Dixon of GCI Group, +1-212-537-8261; or Heather Lusk of Eli Lilly and Company, +1-317-433-5600
COPYRIGHT 2005 PR Newswire Association LLC